ModernaTX
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ModernaTX sits in the top decile of US sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count).
ModernaTX: 90 sponsored US clinical trials, 13 recruiting.
ModernaTX sponsors 90 registered US clinical trials on ClinicalTrials.gov, 13 of them currently recruiting, and 58 completed. 19 of these trials are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Respiratory Syncytial Virus, with 5 trials.
Top-decile sponsor footprint
ModernaTX ranks in the top decile of sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
58 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
90 total, page 1 of 2
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
NCT07496450
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
NCT07089706
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
NCT05992935
A Retrospective Study to Characterize Participants With Propionic Acidemia
NCT05769621
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
NCT05683457
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
NCT05295433
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
NCT05130437
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
NCT04159103
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
NCT07117487
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
NCT06880549
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
NCT06143046
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
NCT06067230
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05831111
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
NCT05701800
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT05575492
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
NCT06189053
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
NCT05164094
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
NCT04899310
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
NCT03897881
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
NCT06634797
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT06508320
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
NCT06097299
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
NCT06097273
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
NCT06060457
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
NCT06033261
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
NCT05975099
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
NCT05972174
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
NCT05868382
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
NCT05827978
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
NCT05827926
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
NCT06130345
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
NCT05815498
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
NCT05827068
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
NCT05765578
Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
NCT06369272
A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
NCT05659264
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
NCT05606965
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
NCT05585632
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT05584202
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 19 |
| Phase 3 | 15 |
| Phase 4 | 4 |
What is open in the ModernaTX pipeline
13 recruiting of 90 indexed (14% open); 58 completed (64%).
Phase mix: 19 late (III/IV) vs 58 early (I/II) (early-phase heavy).
Top condition: Respiratory Syncytial Virus (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ModernaTX: open-pipeline peers nationwide
Peers matched on 90 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
ModernaTX sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 90 trials (± recruiting share)
- Hackensack Meridian Health · 90 trials · 26% recruiting
- National Institute of Dental and Craniofacial Research (NIDCR) · 91 trials · 12% recruiting
- University of Central Florida · 91 trials · 42% recruiting
- Abbott Nutrition · 89 trials · 1% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Masonic Cancer Center, University of Minnesota · 14% recruiting · 249 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
- University of Wisconsin, Madison · 15% recruiting · 1,039 trials
- Dana-Farber Cancer Institute · 14% recruiting · 781 trials
Related
What to do with this ModernaTX page
90 registered trials is a research-attention snapshot, not an endorsement of ModernaTX or any single study.
- 13 of ModernaTX's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Respiratory Syncytial Virus is the condition ModernaTX studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Respiratory Syncytial Virus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ModernaTX pipeline card: 90 registered trials from official public datasets.Report a data error.